BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22066664)

  • 21. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin.
    Kim YH; Demierre MF; Kim EJ; Lerner A; Rook AH; Duvic M; Robak T; Samtsov A; McCulloch W; Chen SC; Waksman J; Nichols J; Whittaker S
    Leuk Lymphoma; 2013 Feb; 54(2):284-9. PubMed ID: 22839723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Romidepsin for the treatment of non-Hodgkin's lymphoma.
    Yazbeck VY; Grant S
    Expert Opin Investig Drugs; 2015; 24(7):965-79. PubMed ID: 25936363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD.
    Brunvand MW; Carson J
    Hematol Oncol; 2018 Feb; 36(1):340-343. PubMed ID: 28560733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
    Reddy SA
    Crit Rev Oncol Hematol; 2016 Oct; 106():99-107. PubMed ID: 27637355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
    J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
    Grant C; Rahman F; Piekarz R; Peer C; Frye R; Robey RW; Gardner ER; Figg WD; Bates SE
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):997-1008. PubMed ID: 20645688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deal watch: Celgene acquires Gloucester pharmaceuticals, gaining approved HDAC inhibitor.
    Nat Rev Drug Discov; 2010 Feb; 9(2):94. PubMed ID: 20118955
    [No Abstract]   [Full Text] [Related]  

  • 28. Nursing Roles in Cardiac Safety: Romidepsin in Patients With T-Cell Lymphoma.
    Hronek J; Reed M
    Oncol Nurs Forum; 2016 Mar; 43(2):227-34. PubMed ID: 26906133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin.
    Sager PT; Balser B; Wolfson J; Nichols J; Pilot R; Jones S; Burris HA
    Cancer Med; 2015 Aug; 4(8):1178-85. PubMed ID: 25914207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
    Duvic M
    Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Romidepsin: a novel histone deacetylase inhibitor for cancer.
    Bertino EM; Otterson GA
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
    Woo S; Gardner ER; Chen X; Ockers SB; Baum CE; Sissung TM; Price DK; Frye R; Piekarz RL; Bates SE; Figg WD
    Clin Cancer Res; 2009 Feb; 15(4):1496-503. PubMed ID: 19228751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
    Martinez-Escala ME; Kuzel TM; Kaplan JB; Petrich A; Nardone B; Rosen ST; Guitart J
    JAMA Oncol; 2016 Jun; 2(6):790-3. PubMed ID: 27054291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Romidepsin for cutaneous T-cell lymphoma.
    Prince HM; Dickinson M; Khot A
    Future Oncol; 2013 Dec; 9(12):1819-27. PubMed ID: 24295412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
    Rangwala S; Zhang C; Duvic M
    Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma.
    Frye R; Myers M; Axelrod KC; Ness EA; Piekarz RL; Bates SE; Booher S
    Clin J Oncol Nurs; 2012 Apr; 16(2):195-204. PubMed ID: 22459529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
    Hymes KB
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):98-109. PubMed ID: 20371442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
    Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
    J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphoma.
    Samimi S; Morrissey K; Anshelevich S; Evans K; Gardner J; Musiek A; Vittorio C; Rook A; Kim E
    J Am Acad Dermatol; 2013 Jan; 68(1):e5-6. PubMed ID: 23244387
    [No Abstract]   [Full Text] [Related]  

  • 40. Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.
    Zinzani PL; Pellegrini C; Cerciello G; Monaco F; Volpetti S; Peli A; Angelucci E; Corradini P; Cox MC; Guarini A; Musso M; Bresciani P; Amato G; Billio A; Caparrotti G; Figuera A; Nassi L; Gaudio F; Grossi A; Onida F; Merli M; Rigacci L; Argnani L
    Leuk Lymphoma; 2016 Oct; 57(10):2370-4. PubMed ID: 26732313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.